EDITOR'S FOREWORD
Of all manifestations of systemic lupus erythematosus (SLE), nephritis is the most extensively studied. This supplement on Lupus Nephritis is intended to highlight advances made in the ®eld in recent years. Of necessity, this is not a comprehensive review of the topic, but instead focuses on current issues and evolving concepts. I am grateful to the Editors of Lupus for their invitation to coordinate this effort and to the many distinguished contributors to this supplement for their enthusiasm in this undertaking.
The supplement is divided into three parts: part 1, Pathogenesis; Part 2, Diagnosis and Monitoring; and Part 3, Management. Dr Argyrios Theo®lopoulos begins the pathogenesis section with a critical overview of transgenic and gene knockout approaches used to de®ne pathogenic genes in lupus nephritis, and a review of genetic studies in lupus-prone mice. He concludes that multiple genetic alterations can lead to the expression of a lupus-like disease in mice. Dr Betty Tsao discusses the exciting recent developments in delineating the genetic basis of SLE and lupus nephritis in humans. She suggests that in addition to SLE susceptibility genes, there may be a separate set of genes predisposing to renal disease.
Dr Syamal K Datta reviews cognate interactions between autoimmune T and B cells in SLE. His work has de®ned nucleosomal antigens to which lupus T cells have high-af®nity receptors (TCR) and prolonged expression of CD40L, a molecule which mediates costimulatory signals to autoimmune B cells. Dr Takashi Kuroiwa and Mr Eric Lee discuss the role of T cells and macrophages in the pathogenesis of lupus nephritis. These cells in®ltrate the kidney and can have profound effects on renal resident cells by releasing soluble cytokines and direct cell-to-cell contact. Dr Joseph Grande discusses the mechanisms underlying the chronic response in progressive renal disease and the role of transforming growth factor and reactive oxygen species in promoting persistent and excessive matrix deposition in lupus nephritis.
In the second part on diagnosis and monitoring, Dr Joseph Grande, a pathologist, joined by Dr James E Balow, a nephrologist, discuss the role of kidney biopsy. Dr Howard Austin III discusses the strengths and limitations of existing methods to evaluate and monitor lupus nephritis. This is followed by an overview of outcome measures for trials of lupus nephritis and proposals for their modi®cations.
The third and last part of this supplement deals with the management of lupus nephritis in adults and children. Drs Mary Anne Dooley and Ronald Falk review existing immunosuppressive therapies and the impact of race on response to therapy. Up to one-third of patients with lupus nephritis may¯are following cessation of immunosuppressive therapy. Drs Claudio Ponticelli and Gabriella Moroni discuss the clinical and pathological correlates of renal¯ares, their prognosis and their management. Dr James M Gloor covers the management of lupus nephritis in children. He cautions clinicians caring for these children that therapeutic decisions made early in the disease may have life-long implications that are not appreciated in the early years of monitoring. Drs Gabor Illei and John H Klippel discuss new experimental approaches that target speci®c stages in the pathogenesis of lupus nephritis. Drs D William Clark and Louise M Moist discuss the role of proteinuria, hypertension and dyslipidemia in the progression of lupus disease. They point out that these are treatable risk factors and deserve further investigation. Dr John H Stone reviews several aspects of end-stage renal disease including disease activity, dialysis and transplantation. Renal transplantation outcomes among SLE patients appear to be inferior to those of non-SLE patients and Dr Stone suggests possible explanations. Ms Marianna Crane, a nurse practitioner, and her interdisciplinary team from NIH point out the complexity of the management of lupus nephritis, for which collaboration with other health professionals is essential. This supplement is dedicated to Dr John L Decker, from the National Institutes of Health in Bethesda, Maryland, whose leadership and vision created an environment in which many world-renowned investigators of SLE thrived. The editor of this supplement has the privilege of identifying several of them as mentors and colleagues. To Drs James E Balow, John H Klippel and Haralambos M Moutsopoulos, now in Athens, Greece, goes my sincere appreciation for making SLE an exciting and rewarding disease to study.
This supplement would not have been possible without the invaluable assistance and dedication of Ms Linda Anderson.
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